Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 61Lymphoma, T-Cell, Cutaneous 42Lymphoma, Follicular 37Lymphoma, B-Cell, Marginal Zone 37Leukemia, Lymphocytic, Chronic, B-Cell 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Non-Hodgkin 36Lymphoma, Mantle-Cell 35Sezary Syndrome 34Mycosis Fungoides 34Lymphoma, Large B-Cell, Diffuse 34Hodgkin Disease 33Multiple Myeloma 32Lymphoma, Large-Cell, Immunoblastic 32Leukemia, Myeloid, Acute 32Burkitt Lymphoma 32Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30Congenital Abnormalities 30Leukemia, Myeloid, Accelerated Phase 27Leukemia, Myeloid, Chronic-Phase 26Waldenstrom Macroglobulinemia 25Lymphoma, Large-Cell, Anaplastic 25Lymphoma 25Myeloproliferative Disorders 24Lymphoma, Extranodal NK-T-Cell 24Leukemia 23Immunoblastic Lymphadenopathy 23Leukemia, Myelomonocytic, Chronic 21Recurrence 20Myelodysplastic Syndromes 19

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1carboxyamido-triazole 1aldesleukin 1Thalidomide 1Paclitaxel 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × fludarabine phosphate × Dermatologic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡